Plasma Protein Therapeutics Market Analysis Highlights Growth To $48.98 Billion By 2030 At 7.2% CAGR

The plasma protein therapeutics sector has been experiencing robust growth, driven by developments in medical treatments and technological advancements. This expanding market is set to continue its upward trajectory as innovations and increasing healthcare demands propel further expansion. Let's explore the market's current size, key drivers, leading companies, and emerging trends shaping the future of plasma protein therapies.

Forecasted Expansion of the Plasma Protein Therapeutics Market Size
The plasma protein therapeutics market has seen significant growth in recent years, with projections indicating an increase from $34.68 billion in 2025 to $37.09 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. This earlier growth phase was propelled by a rise in the prevalence of primary immunodeficiency disorders, growing demand for immunoglobulin treatments, constraints in plasma donation infrastructure, advances in protein purification methods, and regulatory approvals for plasma-based therapies.

Download a free sample of the plasma protein therapeutics market report:
https://thebusinessresearchcompany.com/sample_request?id=9213&type=smp&name=Plasma%20Protein%20Therapeutics%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is expected to maintain strong momentum, reaching $48.98 billion by 2030 with a CAGR of 7.2%. Factors supporting this forecasted growth include the development of recombinant albumin and coagulation factors, wider adoption of subcutaneous administration techniques, increasing healthcare investments in emerging economies, innovations in precision medicine, and enhanced collaborations between public and private sectors aimed at plasma collection. Other significant trends anticipated during this period involve personalized plasma protein therapies, expansion of recombinant protein manufacturing, rising use of subcutaneous delivery methods, heightened awareness of rare blood conditions, and improvements in supply chain and cold chain logistics.

Primary Factors Fueling Growth in the Plasma Protein Therapeutics Market
A growing global incidence of primary immunodeficiency disorders has significantly contributed to the rising consumption of plasma protein therapies. As more patients require immunoglobulin replacement therapies to manage their conditions, the demand for these products continues to climb steadily.

View the full plasma protein therapeutics market report:
https://www.thebusinessresearchcompany.com/report/plasma-protein-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

In parallel, technological advances in protein purification and production have played a crucial role in enhancing the availability and quality of plasma-derived treatments. Improved manufacturing processes and regulatory approvals have facilitated broader market access and acceptance of these therapies.

Top Companies Driving the Plasma Protein Therapeutics Industry
Several leading corporations dominate the plasma protein therapeutics market, including CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, and Octapharma AG.

A notable development occurred in June 2025 when Grifols, a Spain-based provider of plasma-derived therapies such as immunoglobulins, albumin, and clotting factors, acquired Biotest AG. This Germany-based company also specializes in plasma-derived products, including immunoglobulins and coagulation factors. With this acquisition, Grifols aimed to consolidate its plasma protein therapeutic portfolio, optimize operations, and strengthen its foothold in the market.

Innovations Shaping the Future of Plasma Protein Therapeutics
Leading players in the plasma protein therapeutics arena are focusing on pioneering solutions like lyophilized plasma formulations to address the need for portable, stable, and rapidly deployable blood products in emergency and pre-hospital care. These freeze-dried plasma products offer extended shelf lives, simplified storage requirements, and quicker preparation compared to traditional frozen plasma, making them ideal for trauma care and field use.

For instance, in October 2023, Octapharma AG, headquartered in Switzerland, received European medical approval for the lyophilized version of its octaplasLG product. This innovative formulation supports prompt availability, easier handling, and improved stability in critical care settings, enhancing trauma and bleeding emergency management. Octapharma's commitment to advancing plasma-based therapies underscores the importance of such innovations in improving patient outcomes.

Detailed Segmentation of the Global Plasma Protein Therapeutics Market
This market is categorized across several dimensions:
1) By Product Type: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, and Other Products
2) By Administration Route: Intravenous and Subcutaneous
3) By Application Area: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, and others.

Further subdivisions include:
- Immunoglobulin products divided into Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG)
- Albumin types split between Human Serum Albumin and Recombinant Albumin
- Coagulation factors including Factor VIII, Factor IX, and Prothrombin Complex Concentrates
- C1-Esterase Inhibitors broken down into Human and Recombinant forms
- Other products such as Fibrinogen, Alpha-1 Antitrypsin, and various clotting factor concentrates.

This comprehensive segmentation offers a detailed understanding of the market's structure and the diverse therapeutic options available in plasma protein treatments.

New strategic additions in our 2026 market reports include market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.